Cited 36 times in
A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세규 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 박무석 | - |
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 심효섭 | - |
dc.contributor.author | 양우익 | - |
dc.contributor.author | 이익재 | - |
dc.contributor.author | 이주희 | - |
dc.contributor.author | 이창걸 | - |
dc.contributor.author | 최혜진 | - |
dc.contributor.author | 권지은 | - |
dc.date.accessioned | 2014-12-20T16:26:26Z | - |
dc.date.available | 2014-12-20T16:26:26Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/92720 | - |
dc.description.abstract | PURPOSE: This study was undertaken to determine safety and tolerability of nimotuzumab, a humanized anti-epidermal growth factor receptor monoclonal antibody, in combination with radiotherapy in stages IIB-IV non-small cell lung cancer (NSCLC) patients who are unsuitable for radical therapy or chemotherapy. METHODS: Nimotuzumab (100mg, 200mg and 400mg) was administered weekly from week 1 to week 8 with palliative radiotherapy (30-36 Gy, 3 Gy/day). If tumor control was achieved, nimotuzumab was continued every 2 weeks until unacceptable toxicity or disease progression. Serial skin biopsies were collected for pharmacodynamic assessment. RESULTS: Fifteen patients were enrolled in the study, with cohorts of five patients assigned in each dose level of nimotuzumab. Patients and disease characteristics included median age 73 years; Eastern Cooperative Oncology Group performance status (PS) 0-1/2 (n=3/12); female sex (n=2); adenocarcinoma (n=5); never-smoker status (n=2); and stages IIB/IIIB/IV (n=1/8/6). All patients were unable to tolerate radical therapy because of old age or multiple comorbidities. The most commonly reported adverse events were lymphopenia and asthenia (grades 1-2 in most patients). No skin rash or allergic toxicities appeared. Dose-limiting toxicity occurred with pneumonia with grade 4 neutropenia at the 200mg dose of nimotuzumab. Objective response rate and disease control rate inside the radiation field were 46.7% and 100.0%, respectively. CONCLUSIONS: Nimotuzumab in combination with radiotherapy is well-tolerated and feasible. Further clinical investigation of nimotuzumab in NSCLC patients is warranted. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 55~59 | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antibodies, Monoclonal/administration & dosage* | - |
dc.subject.MESH | Antibodies, Monoclonal/adverse effects* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Carcinoma,Non-Small-CellLung/drugtherapy* | - |
dc.subject.MESH | Carcinoma,Non-Small-CellLung/radiotherapy* | - |
dc.subject.MESH | Combined ModalityTherapy | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | LungNeoplasms/drugtherapy* | - |
dc.subject.MESH | LungNeoplasms/radiotherapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Phosphorylation/drug effects | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/antagonists & inhibitors | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/metabolism | - |
dc.subject.MESH | Republic of Korea | - |
dc.title | A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.contributor.googleauthor | Joo Hyuk Sohn | - |
dc.contributor.googleauthor | Chang Geol Lee | - |
dc.contributor.googleauthor | Hyo Sub Shim | - |
dc.contributor.googleauthor | Ik-Jae Lee | - |
dc.contributor.googleauthor | Woo Ick Yang | - |
dc.contributor.googleauthor | Ji Eun Kwon | - |
dc.contributor.googleauthor | Se Kyu Kim | - |
dc.contributor.googleauthor | Moo-Suk Park | - |
dc.contributor.googleauthor | Ju Hee Lee | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.identifier.doi | 10.1016/j.lungcan.2010.04.010 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00602 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01457 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A02219 | - |
dc.contributor.localId | A02300 | - |
dc.contributor.localId | A03055 | - |
dc.contributor.localId | A03240 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A00253 | - |
dc.contributor.localId | A03171 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 20451284 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0169500210001698 | - |
dc.subject.keyword | Nimotuzumab | - |
dc.subject.keyword | Phase I | - |
dc.subject.keyword | Epidermal growth factor receptor (EGFR) inhibitor | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.subject.keyword | Palliative radiotherapy | - |
dc.contributor.alternativeName | Kim, Se Kyu | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Park, Moo Suk | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.alternativeName | Shim, Hyo Sup | - |
dc.contributor.alternativeName | Yang, Woo Ick | - |
dc.contributor.alternativeName | Lee, Ik Jae | - |
dc.contributor.alternativeName | Lee, Ju Hee | - |
dc.contributor.alternativeName | Lee, Chang Geol | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.alternativeName | Kwon, Ji Eun | - |
dc.contributor.affiliatedAuthor | Kim, Se Kyu | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Park, Moo Suk | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Shim, Hyo Sup | - |
dc.contributor.affiliatedAuthor | Yang, Woo Ick | - |
dc.contributor.affiliatedAuthor | Lee, Ik Jae | - |
dc.contributor.affiliatedAuthor | Lee, Chang Geol | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Kwon, Ji Eun | - |
dc.contributor.affiliatedAuthor | Lee, Ju Hee | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 71 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 55 | - |
dc.citation.endPage | 59 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.71(1) : 55-59, 2011 | - |
dc.identifier.rimsid | 28718 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.